top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance

31/03/2026
















Caribou Biosciences' CB-011 received the FDA RMAT designation for multiple myeloma (Ref)


The US FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to Caribou Biosciences' CB-011 (allogeneic anti-BCMA CAR-T) for relapsed or refractory multiple myeloma (r/r MM).


  • The cell therapy is being evaluated in the open-label, multicenter Phase 1 CaMMouflage clinical trial




Comments

bottom of page